Clinical Effects of Atrovastatin Intensive Treatment on Contrast-Induced Nephropathy after Cerebral Vascular Interventional Therapy

Abstract

Abstract: Objective To investigate clinical effects of atrovastatin intensive treatment on contrast-induced nephropathy (CIN) after cerebral vascular interventional therapy援 Methods 95 cases of patients with cerebral vascular diseases requring cerebral vascular interventional therapy in our hospital from July to December 2014 were divided into the observation group (n=49) and control group (n=46). 72 h before operation and after operation, the observation group was given atrovastatin intensive treatment(80 mg, 40 mg), the control group was given atrovastatin treatment (20 mg). The SCR (serum creatinine), CCR (endogenous creatinine clearance), β2-MG( β2-micro globulin), CYS-C (plasma cystatin), hs-CRP (high sensitivity C reactive protein) of two groups were analyzed 24 h before operation and 72h after operation. Results The postoperative renal function and hs-CRP improvement of the observation group was better than that of the control group(P < 0.05). Conclusion The atrovastatin intensive treatment before cerebral vascular interventional therapy can reduce renal damage and is safe, which may be achieved by inhibition of inflammation factor.

Key words: atrovastatin, contrast-induced nephropathy, cerebral vascular interventional therapy, prevention

CLC Number:

R965

LIN Hao-hai ,QIN Chao*,CHENG Dao-bin ,DUAN Song-bo ,WEI Xiao-yong. Clinical Effects of Atrovastatin Intensive Treatment on Contrast-Induced Nephropathy after Cerebral Vascular Interventional Therapy[J]. Chinese Journal of Pharmacovigilance, 2015, 12(5): 267-270.

References

[1] Peter A, McCullough. Contrast-Iuduced Acute Kidney Injury[J].J Am Coll Cardiol, 2008, 51(15):1419-1428.
[2] CaixetaA ,Mehran R. Evidence-based manage ment of patients undergoing PCI: contrast-induced acute kidney injury[J].Catheter Card-iovasc Interv,2010,75(S1):S15-S20.
[3] 李文华,王冬松,李东野,等.大剂量阿托伐他汀预防冠状动脉介入诊疗术后对比剂肾病的临床效果研究[J].中国全科医学 ,2012,15 (30):3463-3465.
[4] 徐验,王丽丽,黄素风,等.大剂量阿托伐他汀对急诊冠状动脉介入治疗患者对比剂肾病的影响[J].岭南心血管病杂志,2012,18（4）:403-404.
[5] ShePherd J, Kastelein J J, Bittner V, et al. Effect of intensive liPid lowering with atorvastatin on renal function in Patients with coronary heart disease: the Treating to New Targets(TNT) study[J].
Clin J Am Soc Nephrol,2007,2(6):1131-1139.
[6] MalhisM，Al-BitarS，Al -DeenZ K. The role of theophylline in prevention of radiocontrast media-induced nephropathy[J]. SaudiJ Kidney Dis Transpl，2010,21 (2) : 276 -283.
[7] 苏海华，姜埃利.造影剂肾病的诊疗进展[J].国际移植与血液净化杂志，2006，5(3): 1-4.
[8] GrubergL，MehranR，DangasG，et al. Acute renal failure requiring dialysis after percutaneous corconary interxentions[J].Cathet Cardi-ovasc Interven，2001,52(4): 409-416.
[9] BariguoriciroldiF，Morici N.New phamacological protocols to pre-vent or reduce contrast media nephropathu[J].Minerva cardioangiol， 2005,53(1):49-58.
[10] SeeligerE，FlemmingB，WronskiT，et al．Viscosity of contrast media perturbs renal hemodynamics[J].J Am Soc Nephrol，2007,18 (11): 2912 -2920.
[11] ItohY，YanoT，SendoT，et al.Involvement of de novoceramide syn-thesis in radio contrast induced renal tubular cell injury [J]. Kidney Int，2006，69 (2): 288 -297.
[12] PeerA，AverbukhZ，BermanS，et al.Contrast media augmented apoptosis of cultured renal mesangial，tubular，epithelial，endothe-lial，and hepatic cells [J].Invest Radiol，2003，38 (3) :177 -182.
[13] AsifA，PrestonRA，Roth D.Contrast-induced nephropathy[J]. Am J Ther，2003，10(2): 137-147.
[14] LaufsU，LiaoJ K.Isoprenodid metabolism and the pleiotropic ef-fects of statins[J].Curr Aheroscler Rep，2003,5 (5) : 372 -378.
[15] RichardA，ZagerAC，JohonsonS，et al.Radiographic contrast media－induced tubular njury: evaluation of oxidant stress and pasma mem-brane integrity[J].Kidney Int，2003，64(1): 128 -139.
[16] BaligaR，UedaN，Walker PD，et al. Oxidant mechanisms in toxic a-cute renal failure[J].Am J Kindney Dis，2007，29 (3) : 465 -477.
[17] GoldenbergI，Matetzky S.Nephropathy induced by contrast me-dia:pathogenesis，risk factors and preventive strategies[J].Can Med AssocJ，2005，172 (11): 1461 -1471.
[18]汪斌，刘志忠，张丰富.冠状动脉介入诊治中超敏 C反应蛋白与对比剂肾病的相关性分析[J].中国医药，2007，2 (8) : 457-459.
[19]苏津自，薛艳，蔡文钦，等.超敏 C反应蛋白水平与阿托伐他汀对急性冠脉综合征患者对比剂所致肾功能损害影响的关系[J].中华心血管病杂志，2011，39 (9): 807 -811.
[20] Patti G, Nusca A, ChelloM，et a1. Usefuless of statin pretreat-ment to prevent contrast-induced nephropathy and to improve long -term outcome in patients undergoing percutaneous coronary intervention[J].Am J Cardiol，2008，101 ( 3): 279 -285.
[21] 贾宁人，卢鸿浩，吴家明，等.血清 CysC测定对于判断早期肾功能损害的应用评价[J].放射免疫学杂志，2010，23(5):567-569.